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benign and malignant cases. Results: In 2008-2009 there were 477904 screening 
mammography examinations in Hungary. 5.15 % of participating women were re-
called. The attendance of re-called women was 92.25 %. Altogether 2092 women 
(9.7 %) were referred for breast surgery but only 1485 women (71.0 %) underwent 
surgery. Histological examination confirmed 281 benign (18.9 %) and 1204 malignant 
(81.1 %) cases. ConClusions: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international pro-
fessional guidelines. However, in addition to current indicators, new ones should be 
introduced in order to provide a more comprehensive monitoring of the program.
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objeCtives: Organized, nationwide screening for breast cancer with mammog-
raphy started in Hungary in January 2002. Women in the age group 45-65 years 
are the target population and 2 years screening interval is applied. The aim of 
this study is to analyze the attendance rate of the 4th screening round (2008-
2009). Methods: The data derive from the financial database of the National 
Health Insurance Fund Administration (NHIFA) covering the period of 2008-2009. 
We calculated two attendance indicators. The up-take of the program means 
the percentage of women aged 45-65 who, having been sent an invitation for 
screening, attend a screening unit and undergo mammography in response to 
that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic mam-
mography. Results: In 2008-2009 there were 477904 screening mammography 
cases and 1204893 diagnostic mammography examinations in Hungary. We found 
49.4 % and 41.5 % up-take in 2008 and 2009 respectively; and 45.0 % combined 
rate for 2008/2009. The screening coverage was 31.2 % and the diagnostic cover-
age was 20.4 %, while the total coverage (screening and diagnostic) was 50.1 
%. ConClusions: The attendance of the Hungarian organized breast cancer 
screening program – compared to the previous period before the implementa-
tion of the organized screening program – is promising, although to achieve the 
expected results in mortality decrease a further improvement of both the uptake 
and coverage is necessary.
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objeCtives: Recent advances in prostate cancer radiation therapy (RT) technology 
have led to the development of costlier treatments such as intensity-modulated 
radiation therapy (IMRT) compared to the prior standard, conventional radiation 
therapy (CRT). This study examines the two treatment modalities to determine if 
racial disparities in morbidity and disease control may be explained by differential 
use of IMRT versus CRT. Methods: A population-based study was conducted 
using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 
from 2000 through 2009 for patients with non-metastatic prostate cancer. Adjusted 
Cox Proportional Hazards models were conducted, adjusting for demographic 
and clinical characteristics. Results are presented as (Adjusted Hazard Ratio [95% 
Confidence Interval]). In subjects without prior morbidity at RT, the rate of recur-
rence, hip fracture, erectile dysfunction, disorders related to gastrointestinal, 
and urinary (incontinence and non-incontinence) morbidity were compared by 
race with IMRT as the referent group. Results: Approximately 10,976 men [524 
African-American (AA) CRT; 423 AA IMRT; 4,746 Caucasian CRT; 5,283 Caucasian 
IMRT] met study eligibility. Diffusion of IMRT was slower among AA compared 
to Caucasians (p< 0.001). Caucasians receiving CRT were at a greater risk for hip 
fracture [1.29; (1.16, 1.43)], cancer recurrence [1.13; (1.04, 1.23)], or urinary incon-
tinence [1.09; (1.01, 1.19)] than those receiving IMRT. No estimates comparing 
AA CRT recipients to AA IMRT recipients reached statistical significance, though 
cancer recurrence, erectile dysfunction, and gastrointestinal morbidity rates were 
greater for CRT subjects ConClusions: There were no statistically significant 
racial disparities in morbidity and disease control related to differential use of 
IMRT versus CRT. However, diffusion of IMRT was significantly slower among AA. 
Future research should include more years of follow-up data and a larger sample 
of AA in order to understand whether measured differences in treatment diffusion 
achieve clinical significance sufficient to explain a portion of the racial disparity 
in prostate cancer mortality.
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comparisons. ConClusions: Current standards around second-line treatment of 
mCRC have evolved over time. The substantial clinical, methodological, and sta-
tistical heterogeneity in the available data prevents evidence-based quantitative 
comparisons of treatment outcomes at this time.
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objeCtives: This study compares everolimus (EVE) versus the most commonly 
used chemotherapy agents in UK clinical practice (capecitabine [CAPE], docetaxel 
[DOC] and doxorubicin [DOX]) in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer with the purpose of determining 
the effect of everolimus versus chemotherapy through the derivation of hazard 
ratios (HR). Methods: A systematic review of the literature was performed to find 
evidence that could link EVE with chemotherapy (CAPE, DOC and DOX) in terms 
of progression-free survival (PFS) and overall survival (OS). No head-to-head tri-
als comparing EVE versus chemotherapy were found, the only study that linked 
hormonal therapy with chemotherapy for treatment of metastatic breast cancer 
was Wilcken et al. (2003). Wilcken et al. identified three studies which compared 
OS for tamoxifen versus chemotherapy. None of the studies identified in the sys-
tematic review reported PFS. The link between EVE versus chemotherapy through 
Wilcken et al.(2003) was established via tamoxifen (using Bucher methods), so it 
was assumed that PFS for chemotherapy would be the same as PFS for everolimus 
versus tamoxifen (TAM) from the TAMRAD trial. Results: HR for everolimus versus 
tamoxifen for PFS from the TAMRAD trial is 0.54. For OS, Wilcken et al. derived a HR 
for chemotherapy versus tamoxifen of 0.94. To calculate the HR for OS for everoli-
mus vs tamoxifen the inverse was applied to the OS HR from the TAMRAD trial 
(0.45), hence (1/0.45)= 2.22. The HR for OS for everolimus versus chemotherapy is 
therefore (0.94x2.22)= 2.09. Because a class effect was assumed for the three chemo-
therapy agents, these HRs were applied to capecitabine, docetaxel and doxorubicin 
equally. ConClusions: Compared with the most commonly used chemotherapy 
agents in UK clinical practice (CAPE, DOC and DOX), everolimus has a lower risk of 
death as demonstrated by the HRs derived.
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objeCtives: Lung cancer is the most common cause of cancer-related deaths 
world-wide. Afatinib is a novel, potent, irreversible ErbB family blocker. In EGFR 
mutation-positive locally advanced and metastatic non-small cell lung cancer, 
afatinib shows superior effectiveness as a 1st-line treatment compared to stand-
ard-of-care chemotherapy. To date, no head-to-head trial results exist to compare 
the efficacy of afatinib to reversible EGFR TKIs, gefitinib or erlotinib. The analy-
ses presented here attempt to fill this gap by means of a network meta-analysis 
(NMA). Methods: A systematic literature review (2002-2012) identified the best 
available evidence. Results from afatinib’s pivotal trials (LUX-Lung 3, LUX-Lung 6) 
were added. A NMA following a Bayesian approach (in WinBUGS) was applied to 
estimate the relative treatment effects between afatinib, gefitinib and erlotinib. 
Outcomes of interest were progression free survival (PFS) and overall survival (OS). 
For PFS, results by investigator review were considered as not in all trials PFS was 
assessed independently. Versus erlotinib, afatinib’s results in the two most common 
EGFR mutations studied in erlotinib trials were considered. Sensitivity analyses were 
performed to confirm the robustness of results. Results: Twenty studies, includ-
ing LUX-Lung 3 and LUX-Lung 6, were included; 19 reported OS, 14 reported PFS. 
Results from random effects models are reported. All comparisons versus reversible 
TKIs favoured afatinib, although in most analyses the upper credible interval limit 
exceeded 1. The estimated probability of afatinib being best regarding PFS in all 
mutations was 80% compared to 17% for erlotinib and 3% for gefitinib, and was 43% 
regarding OS compared to 13% for gefitinib and 3% for erlotinib. ConClusions: 
Afatinib consistently showed superior efficacy versus chemotherapy in the pivotal 
trials. In the absence of head-to-head trial results versus reversible TKIs, the NMA 
results suggest also potential superiority of afatinib for both PFS and OS when 
compared to erlotinib and gefitinib.
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objeCtives: Organized, nationwide screening for breast cancer with mammogra-
phy started in Hungary in January 2002. Women in the age group 45-65 years are the 
target population and 2 years screening interval is applied. The aim of this study is 
to evaluate the quality indicators of the 4th screening round (2008-2009). Methods: 
The data derive from the financial database of the National Health Insurance Fund 
Administration (NHIFA) covering the period of 2008-2009. We calculated the follow-
ing indicators: recall rate of women who underwent mammography examinations, 
attendance of re-called women, proportion of women referred to surgery, proportion 
of women who underwent surgery compared to referred women, proportion of 
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objeCtives: With a vast number of possible treatment options for Multiple 
Myeloma patients, it is unclear in which combination and sequencing compounds 
should be used to achieve prolonged overall survival. This question cannot be timely 
answered with an RCT, a health economic model (1) was used to approximate for 
OS and adopted for a German cost setting. Methods: Using a combination of 
meta-analysis and -regression, the possible overall survival of different therapy 
sequences is approximated in a Markov model. Data source for this model is a 
systematic literature research covering 2008-2012, identifying a total of 68 studies 
and 11.115 patients in Multiple Myeloma. From each study treatment arm, response 
per therapy and therapy line was extracted. Subsequently, a regression analysis was 
used to specifically determine the “time to next treatment (TTNT)”. TTNT is used 
in our model study to reflect the positive correlation of response to therapy and 
disease progression, which has shown to be highly related (2-5). Using TTNT, the 
model can now demonstrate which sequence of therapies in 1st, 2nd and 3rd line 
will total to a possible OS of a patient. Results: We analyzed 13 sequences from 
over 200 theoretical combinations, based on their German approval. Early usage of 
new compounds results in a prolongation of overall survival of at least 6 months, 
compared to the standard therapy with melphalan/prednisone (6), with minimal 
possible OS between 3.98 and 5.06 years. Cost data from Germany were included 
to amount costs of therapy for a complete sequence. For the sequences presented, 
costs range between 69.000 and 135.000 € . The majority of those costs accrue from 
drugs, not from other resources. ConClusions: An important topic of modeling 
approaches is to show both internal and external validity, which is both needed to 
validate the prognoses. The external validation is currently undertaken using data 
from cancer registries and non-interventional studies.
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objeCtives: Standard therapy for chronic lymphocytic leukaemia (CLL) is fludara-
bine, followed by alemtuzumab. Patients resistant to both treatments (double refrac-
tory (DR)-CLL) receive best supportive care (BSC). Ofatumumab is licensed for the 
treatment of DR-CLL, but was not recommended by the National Institute for Health 
and Care Excellence (NICE technology appraisal 202 (TA202)). There is little clinical 
data for BSC in DR-CLL. TA202 identified a single-arm study of ofatumumab and 
an observational study of BSC. Survival for BSC in TA202 was modelled by fitting a 
Weibull distribution to data for ofatumumab non-responders. The effects of ofatu-
mumab were estimated by assuming a proportional hazards model. The objective of 
this study was to investigate the potential sources of survival data for BSC, and the 
impact of the choice of survival distributions used in TA202 on the cost-effectiveness 
of ofatumumab. Methods: Individual patient-level data was reconstructed from 
Kaplan-Meier curves using a published algorithm. Plausible survivor functions were 
fitted to the data using Markov chain Monte-Carlo simulation. Goodness-of-fit to 
the observed data was assessed using deviance information criterion and the clini-
cal plausibility of extrapolations using subjective opinion. The cost-effectiveness 
model from TA202 was reproduced including alternative survival data. Results: 
A Weibull distribution provided the best fit to the data and was most clinically 
plausible. If proportional hazards were assumed (as in TA202) the incremental cost-
effectiveness ratio (ICER, incremental cost per life year gained) was £52,400, simi-
lar to £49,252 reported in TA202. Relaxing the assumption of proportional hazards 
increased the ICER to £85,618. ConClusions: The best fitting and most clinically 
plausible model was a Weibull distribution, giving results consistent with TA202; 
however both the use of a subgroup of a single arm trial and of data from multiple 
studies has a high level of uncertainty. Relaxing the assumption of proportional 
hazards increased the ICER.
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objeCtives: The VELOUR trial demonstrated significant survival benefit for afliber-
cept plus FOLFIRI (5-fluorouracil-leuocovorin-irinotecan) versus FOLFIRI alone in 
mCRC patients previously treated with oxaliplatin. Multivariate analysis identified 
a subset of “better responder” patients who derive sustained benefit with AF, which 
includes patients who did not experience an early relapse directly from adjuvant 
setting (10% of patients included in VELOUR) and with either ECOG PS0 or (PS1 and 
≤ 1 metastatic site). Median OS was significantly improved in AF arm: 16.2 versus 
13.1 months for PF (adjusted HR = 0.73 [95% CI: 0.61–0.86]). Mean survival estimation 
can render a more meaningful estimate for long-term benefit of interventions and 
can be effectively applied to clinical and economic decision support. Our objective 
was to derive mean OS for the “better responders” subgroup in VELOUR. Methods: 
As survival probability at the end of the follow-up period was 21% in AF vs 8% in PF, 
mean OS was estimated by extrapolating the KM curve using a survival function over 
a 15-year period. Five standard parametric distributions were tested: exponential, 
Weibull, lognormal, loglogistic and Gompertz. Goodness-of-fit of distributions was 
evaluated by Akaike’s Information Criteria (AIC), Bayesian Information Criteria (BIC) 
and graphical methods. Results: Of the 1226 patients enrolled in VELOUR, 404 
objeCtives: Off-label use of medications is extremely common especially in 
oncology. The aim of this study is to help update the guidelines and determine 
pharmaceuticals and off-label indications in breast cancer. Methods: This study 
involved patients (n= 1317) with metastatic breast cancer with tumors that were 
defined as human epidermal growth factor receptor 2, ErbB-2 positive who received 
trastuzumab or other medicine application off-label usage in Turkey. During this 
period using trastuzumab was licenced only for 9 weeks, not for 52 weeks in Turkey. 
A computer search was performed using the TITCK’s ( Turkish Drug and Medical 
Devices Institution) database. The patient base was searched for off-label medi-
cine applications between 1 June 2008 to 1 June 2010. Results: The average age 
were 49.02 ± 10.46. Overall, 85 % of applications were approved in generally 8 or 9 
weeks period. It was found that the Marmara Region had the highest application 
percentage (33.26 %) and then the Central Anatolia Region (27.9 %). Evaluated on 
the base of cities Istanbul, Ankara and Izmir had the most applications with 29.6 
%, 19.2 % and 15.7 % respectively. University hospitals were created the most of 
the applications (81.1%), other applicaitons were from education & research hos-
pitals (10.2 %) and private hospitals ( 5.9 %). Off-label drug usage in breast cancer 
medication, physicians were preferred trastuzumab, trastuzumab+vinoralbin and 
lapatinib. ConClusions: Trastuzumab had the highest percentage in all off-label 
medicine applications for breast cancer usage. On the other hand, 85 % of all tras-
tuzumab off-label usage applications were approved. The reason of 15 % of trastu-
zumab applications is needed to be investigated further.
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objeCtives: To assess the patient population with advanced non-small cell lung 
cancer (NSCLC) with EGFR (epidermal growth factor receptor) positive mutation 
in Germany who are eligible for tyrosine-kinase inhibitor (TKI) therapy. An accu-
rate assessment of the relevant patient population provides the basis for budget 
impact analyses in health technology assessments. Methods: A systematic litera-
ture review was conducted. In addition, data from various cancer registries, cohort 
studies and surveillance studies were analyzed and compared with the findings 
in the literature. Results: In a first step the proportion of patients with NSCLC 
was determined. Data was further differentiated by histologic subgroup (adeno-
carcinoma, large-cell carcinoma, squamous carcinoma and other carcinoma). The 
analysis revealed that the proportion of adenocarcinoma among the group of NSCLC 
has increased in Germany, especially among women from about 40% in 2000 to over 
58% in 2009, in men from 28% to almost 40%, respectively. The proportion of patients 
with locally advanced or metastatic NSCLC (stage IIIb/IV) ranged between 51%-70%. 
The proportion of patients harbouring an EGFR mutation ranged between 5%-17%, 
differing by histologic subgroup, with the highest EGFR mutation rates (9%-26%) 
in patients with adenocarcinoma. The distribution of patients by ECOG (Eastern 
Cooperative Oncology Group) Performance Status (PS) showed that at diagnosis 63%-
92% had an ECOG-PS 0-1. On average, first line therapy was received by over 80% of 
patients, while only 52%-65% underwent second line therapy and third line therapy 
was received by 15%-25% only. ConClusions: By analyzing all available data it is 
possible to provide good estimates of the relevant patient population. Although 
significant advances have been made in reporting and data collection for relevant 
patient subgroups related to NSCLC, there still is a large lack of representative data 
on a national level in Germany.
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objeCtives: Prostate cancer (PC) is the most common solid neoplasm in Europe. 
Accurate estimates of prevalence and patient flow through PC states are necessary 
to analyse disease burden and the health economic impact of novel therapies. This 
study presents a dynamic patient progression model (PM) estimating the popula-
tion size of 13 PC clinical states across 8 European countries (EU8; Belgium, France, 
Germany, Italy, The Netherlands, Spain, Sweden, and UK). Methods: A dynamic 
PM was developed using a 27-year time horizon to estimate the prevalence and 
progression of PC from diagnosis through possible death, using a sequence of 13 
Markov clinical states (5 non-metastatic and 8 metastatic). Incidence data were 
taken from local country registries from 1993 to 2012, and a simple growth model 
was used to forecast incidence rates to 2020 and beyond. PM flow structure, prob-
abilities of prevalence, progression, and mortality per clinical state were determined 
using a Delphi panel of PC experts from the EU8 countries and based on published 
literature and local research. Results: A consensus of expert opinion was reached 
on the clinical states and flow rates of patients with PC in Europe. This resulted in 
a refined PM with new clinical states that represent the current treatment para-
digm for PC. The PM also estimated growth in prevalence and mortality of future 
PC patient populations across 13 different clinical states of PC from 2012 to 2020. 
Five-year prevalence rates from the PM were in agreement with those from the 
GLOBOCAN 2008 project. ConClusions: The PM obtained by consensus of expert 
opinions provided patient prevalence and mortality estimates for 13 distinct PC 
clinical states. The PM and patient flow rates provide a representative simulation 
of the local environment, which can be used to assess PC disease burden, health 
economic impact, and cost of PC care in the EU.
